2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1640

Cutaneous and Musculoskeletal Clinical Characterization of a Cohort of Patients with Chronic Graft-versus-host Disease
Abstract Number: 775

Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin
Abstract Number: 861

Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE
Abstract Number: 534

CXCL13 Serum Levels and Circulating Follicular Helper T-Cells Decrease After Co-stimulation Blockade with Abatacept in Rheumatoid Arthritis
Abstract Number: 1047

CXCL4-L1 Levels Are Elevated in Systemic Sclerosis Patients and Correlate with Pulmonary Arterial Hypertension and Capillaroscopic Indices of Vascular Damage
Abstract Number: 1410

Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Μechanism of Αction in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis
Abstract Number: 2593

Cyclophosphamide for the Treatment of Skin Fibrosis in Systemic Sclerosis: A Systematic Review
Abstract Number: 1705

Cyclophosphamide Therapy for the Neurologic Involvement of Behçet’s Disease – Is It Superior to Azathioprine in Preventing Relapses?
Abstract Number: 15

CYR61/TGF-β Axis Promotes Adventitial Fibrosis of Takayasu Arteritis in the IL-17 Mediated Inflammatory Microenvironment
Abstract Number: 2527

Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
Abstract Number: 1781

Cytokine Dependence of Enthesis-resident Lymphocytes in Murine Spondyloarthritis
Abstract Number: 543

Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients
Abstract Number: 1070

Cytokine Signatures Differentiate Systemic Sclerosis Patients at High versus Low Risk for Pulmonary Arterial Hypertension
Abstract Number: 560

Dactylitis Occurrence in Early Spondyloarthritis: Five Years Data from a French National Prospective Cohort
Abstract Number: 1277

Damage and Comorbidities in a Cohort of Patients with Idiopathic Inflammatory Myopathy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].